Assessment With CCTA and MRI in Asymptomatic Patients With Type 2 Diabetes for Detection of Unrecognized Myocardial Scar in Subclinical Coronary Atherosclerosis (ACCREDIT)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
This study is aimed to answer the clinical question of the prevalence of myocardial scar in asymptomatic patients with type 2 Diabetes Mellitus with a special focus on the diagnostic efficacy of Xenetix® 350-enhanced 64-rows MDCT for the visualisation of the coronary arterial tree and secondarily for the assessment of myocardial viability when using Dotarem® enhanced-cardioMR as the gold standard examination.
Assessment With Cardiac Computed Tomography Angiography (CCTA) and Magnetic Resonance Imaging (MRI) in Asymptomatic Patients With Type 2 Diabetes for Detection of Unrecognized Myocardial Scar in Subclinical Coronary Atherosclerosis
Actual Study Start Date :
Actual Primary Completion Date :
Estimated Study Completion Date :
Resource links provided by the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
50 Years to 75 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patient with onset of type 2 diabetes occurred at age 30 years or older
Patient between the ages of 50 and 75 years at enrolment time
Patient with at least two identified cardiac risk factors who will undergo a CMR and a CCTA examinations to evaluate his/her coronary and cardiac status
Patient with angina pectoris or chest discomfort
Patient with stress test or invasive coronary angiography within the prior 3 years
Patient with history of myocardial infarction, overt non compensated heart failure, or coronary revascularization
Patient with hemodynamic instability.
Patient with a contraindication or intolerance to Beta-Blocker administration